Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Other financing activities (2022 - 2025)

Sagimet Biosciences' Other financing activities history spans 4 years, with the latest figure at $1000.0 for Q2 2025.

  • Quarterly Other financing activities fell 96.3% to $1000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $1000.0 through Dec 2025, down 99.9% year-over-year, with the annual reading at $1.0 million for FY2024, 70.3% down from the prior year.
  • Other financing activities came in at $1000.0 for Q2 2025, down from $27000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $1.0 million in Q1 2024 to a low of $1000.0 in Q2 2025.
  • The 4-year median for Other financing activities is $95500.0 (2022), against an average of $357833.3.
  • The largest YoY upside for Other financing activities was 648.53% in 2024 against a maximum downside of 97.03% in 2024.
  • Sagimet Biosciences' Other financing activities stood at $55000.0 in 2022, then soared by 1554.55% to $910000.0 in 2023, then tumbled by 97.03% to $27000.0 in 2024, then crashed by 96.3% to $1000.0 in 2025.
  • Per Business Quant, the three most recent readings for SGMT's Other financing activities are $1000.0 (Q2 2025), $27000.0 (Q2 2024), and $1.0 million (Q1 2024).